Descriptive only

Death by suicide

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)

Randomized trials

Treatments

14,225

Participants

Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 43 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagEligibility, bmi entry range: a design requires bmi 50 or more while another admits only 35 or less
NoteOutcome assessment, time point: selected time points span 5 to 78.21 weeks
NoteOutcome assessment, analysis set: mixed: completers 1, full_analysis 2, modified_itt 3, other 4, randomized 4, safety 29
NoteOutcome assessment, definition: mixed: ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms 1, C-SSRS post baseline category 1, Grade 3, needing third party assistance 1, Hypoglycemia adverse event of special interest 1, hypoglycemia requiring medical assistance 1, minor: symptoms with glucose below 3 mmol/L, self treated or resolved 1, minor: symptoms with glucose below 3.0 mmol/L, self treated 1, not stated 21, plasma glucose 54 mg/dL or lower 1, Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms 1, severe hypoglycemia 1, severe hypoglycemia needing assistance of another person 1, Severe hypoglycemia needing assistance with glucose below 36 mg/dL or prompt recovery 1, Severe hypoglycemia requiring assistance of another person 1, severe hypoglycemia requiring third party assistance 1, severe symptomatic hypoglycemia needing assistance 1, severe symptomatic hypoglycemia needing assistance of another person, glucose below 2.0 mmol/L or prompt recovery 1, severe, requiring assistance of another person 2, symptomatic hypoglycemia confirmed below 3.3 mmol/L 1, symptomatic mild hypoglycemia, no glucose threshold printed 1, TEAE leading to death 1, Zero implied by no hypoglycemia episodes of any kind 1
NoteOutcome assessment, adjudicated: mixed: not stated 42, yes 1
NoteOutcome assessment, proportion method: mixed: not stated 41, observed 2
NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 42, while_on_treatment 1
NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 42, treatment_policy 1
NoteRisk of bias, blinding: mixed: double_blind 25, open_label 16, single_blind 2
NoteRisk of bias, funding: mixed: industry 36, mixed 4, non_industry 3
NoteData handling, input conversions: arms_combined 15, printed_denominator 7

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
NCT03131687	30	safety	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT02325960	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2015	age 18 to 70; BMI 24 or more; HbA1c 7.0 to 10.0 percent; metformin 1.5 g/day or more
PIONEER 4	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
MAGNA VICTORIA	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2015	South Asian descent; age 18 to 74; BMI 23 or more; HbA1c 6.5 to 11.0 percent
Lixilan-O-AP	24.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD
PIONEER 10	57	safety	not stated	not stated	yes	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
NCT00765817	30	full_analysis	minor: symptoms with glucose below 3 mmol/L, self treated or resolved	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults 18 or older; insulin glargine 20 U/d or more alone or with metformin or pioglitazone; HbA1c 7.1 to 10.5 percent; BMI 45 or less
NCT05579977	28	safety	C-SSRS post baseline category	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
GETGOAL-L-ASIA	24	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
NCT03951753	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 20 to 74; BMI 25 to 45; metformin with or without one other oral agent
NCT00960661	30	other	minor: symptoms with glucose below 3.0 mmol/L, self treated	not stated	not stated	observed	not stated	not stated	open_label	industry	2009	age 18 or older; T2D on insulin glargine and metformin with or without sulfonylurea; HbA1c 7.0 to 10.0; BMI 25.0 (23.0 in South Korea) to 45.0; HbA1c above 7.0 after optimization
NCT00577824	24	full_analysis	Severe hypoglycemia requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy
GetGoal-Duo1	24	safety	symptomatic hypoglycemia confirmed below 3.3 mmol/L	not stated	not stated	observed	not stated	not stated	double_blind	industry	2009	T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in
NCT01558271	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
AWARD-CHN1	26	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
AWARD-8	24	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose
LixiLan-G	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	T2D 1 year or more; HbA1c 7 to 9 percent; BMI over 20 to 40; maximum tolerated GLP-1 RA plus metformin
SUSTAIN	35	safety	Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
AWARD-CHN2	52	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
NCT02212067	17	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to 64; HbA1c 6.5 to 9.0 percent; BMI 20 to 35; diet and exercise or metformin
NCT00744926	24	safety	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45
ELEGANT	26	randomized	Grade 3, needing third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain
PIONEER 11	31	safety	ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more
SUSTAIN™ 5	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
DUAL™ I Japan	53	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2015	Japanese adults 20 or older; HbA1c 7.0 to 11.0 percent; BMI at least 20; insulin naive on one oral drug
NCT05086445	14	safety	Hypoglycemia adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
LIXILAN JP-O1	52.43	safety	TEAE leading to death	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
NCT02887625	78.21	other	severe hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2015	age 18 to 75; HbA1c above 7.5 percent on near maximal metformin plus sulfonylurea
SUSTAIN™	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
NCT02288273	14	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to 75; T2D on metformin 1500 mg or more; HbA1c 7.0 to 10.0 percent; BMI 45 or less
Lixilan-L-CN	30.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
GETGOAL-M	24	safety	severe symptomatic hypoglycemia needing assistance of another person, glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less
NCT01455441	16	completers	Zero implied by no hypoglycemia episodes of any kind	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	age over 18; HbA1c 7 to 11 percent; BMI over 25; diet or metformin; sedentary
NCT03311724	16	modified_itt	plasma glucose 54 mg/dL or lower	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
NCT04466904	20	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; T2D on diet and exercise or stable metformin; HbA1c 7.5 to 11.0 percent; BMI 20 to 35
NCT00700817	52	other	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months
S002858	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry		T2D age over 35; clinical CKD; eGFR above 30 mL/min; stable ACE inhibitor or ARB
S002885	12	other	symptomatic mild hypoglycemia, no glucose threshold printed	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2019	age 20 to 75; HbA1c 7.0 or more on metformin and glimepiride; eGFR 30 or more
S002928	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	non_industry	2022	age 18 to 65; BMI 50 or more; type 2 diabetes
S002984	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2020	T2D age 45 or older; HbA1c 7.0 to 11.0 percent; metformin at least 3 months
S002992	26.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry		adults 18 or older; HbA1c 7.5 to 10 percent; BMI 20 to less than 40; basal insulin 20 to 50 U plus metformin with or without SGLT2i
S003047	6.57	safety	Severe hypoglycemia needing assistance with glucose below 36 mg/dL or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin
S003079	5	safety	hypoglycemia requiring medical assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT03131687	A1	PLACEBO	30	arm, events	0 / 51		R0016215:Table 3
NCT03131687	A2+A3+A4+A5	TIRZ_SC	30	arm, events	0 / 213	arms_combined	R0016215:Table 3
NCT03131687	A6	DULA_SC	30	arm, events	0 / 54		R0016215:Table 3
NCT02325960	A1	EXEN_SC	16	arm, events	0 / 22		R0024438:Results
NCT02325960	A2	INS_GLARGINE	16	arm, events	0 / 23		R0024438:Results
PIONEER 4	A1	SEMA_PO	57	arm, events	0 / 285		R0015836:Supplement Table S6
PIONEER 4	A2	LIRA_SC	57	arm, events	0 / 284		R0015836:Supplement Table S6
PIONEER 4	A3	PLACEBO	57	arm, events	0 / 142		R0015836:Supplement Table S6
MAGNA VICTORIA	A1	LIRA_SC	26	arm, events	0 / 22		R0020542:Results
MAGNA VICTORIA	A2	PLACEBO	26	arm, events	0 / 25		R0020542:Results
Lixilan-O-AP	A1	IGLARLIXI_SC	24.43	arm, events	0 / 351		R0013321:Results
Lixilan-O-AP	A2	INS_GLARGINE	24.43	arm, events	0 / 350		R0013321:Results
Lixilan-O-AP	A3	LIXI_SC	24.43	arm, events	0 / 177		R0013321:Results
PIONEER 10	A1+A2+A3	SEMA_PO	57	arm, events	0 / 393	arms_combined	R0018421:Table 2
PIONEER 10	A4	DULA_SC	57	arm, events	0 / 65		R0018421:Table 2
NCT00765817	A1	EXEN_SC	30	arm, events	0 / 138		R0027069:Table 3
NCT00765817	A2	PLACEBO	30	arm, events	0 / 123		R0027069:Results
NCT05579977	A10+A11+A12+A13+A9	LOTI_PO	28	arm, events	0 / 325	arms_combined	registry:outcomes
NCT05579977	A8	PLACEBO	28	arm, events	0 / 64		registry:outcomes
GETGOAL-L-ASIA	A1	LIXI_SC	24	arm, events	0 / 154		R0022626:Results
GETGOAL-L-ASIA	A2	PLACEBO	24	arm, events	1 / 157		R0022626:Results
NCT03951753	A1	TIRZ_SC	32	arm, events	0 / 45		registry:adverse_events
NCT03951753	A2	SEMA_SC	32	arm, events	0 / 44		registry:adverse_events
NCT03951753	A3	PLACEBO	32	arm, events	0 / 28		registry:adverse_events
NCT00960661	A1	EXEN_SC	30	arm, events	0 / 316		R0016788:Results
NCT00960661	A2	INS_LISPRO	30	arm, events	0 / 321		R0016788:Figure 1
NCT00577824	A1	PLACEBO	24	arm, events	0 / 36		R0018881:Results
NCT00577824	A2+A3	EXEN_SC	24	arm, events	0 / 145	arms_combined	R0018881:Results
GetGoal-Duo1	A1	PLACEBO	24	arm, events	0 / 223		R0026107:Results
GetGoal-Duo1	A2	LIXI_SC	24	arm, events	0 / 223		R0026107:Results
NCT01558271	A1	DULA_SC	52	arm, events	0 / 281		R0011754:Table 2
NCT01558271	A2	LIRA_SC	52	arm, events	0 / 141		R0011754:Table 2
AWARD-CHN1	A1	DULA_SC	26	arm, events	0 / 244		R0014229:Table 2
AWARD-CHN1	A3	GLIMEPIRIDE	26	arm, events	0 / 245		R0014229:Table 2
AWARD-8	A1	DULA_SC	24	arm, events	0 / 240		R0016038:Results
AWARD-8	A2	PLACEBO	24	arm, events	0 / 60		R0016038:Results
LixiLan-G	A1	IGLARLIXI_SC	26	arm, events	0 / 257		registry:adverse_events
LixiLan-G	A2	GLP1RE_SC	26	arm, events	0 / 257		registry:adverse_events
SUSTAIN	A1	SEMA_SC	35	arm, events	0 / 288		R0014802:Results
SUSTAIN	A3	SITAGLIPTIN	35	arm, events	0 / 290		R0014802:Table 3
AWARD-CHN2	A2	DULA_SC	52	arm, events	0 / 257		R0023722:Table 2
AWARD-CHN2	A3	INS_GLARGINE	52	arm, events	0 / 259		R0023722:Table 2
NCT02212067	A1	SEMA_SC	17	arm, events	0 / 37		R0021892:Supplement Table 2
NCT02212067	A2	PLACEBO	17	arm, events	0 / 38		R0021892:Supplement Table 2
NCT00744926	A1	PLACEBO	24	arm, events	0 / 123	printed_denominator	R0025346:Results
NCT00744926	A2+A3	TASP_SC	24	arm, events	0 / 245	printed_denominator;arms_combined	R0025346:Results
ELEGANT	A1	LIRA_SC	26	arm, events	0 / 26		R0025175:Results
ELEGANT	A2	STANDARD_CARE	26	arm, events	0 / 24		R0025175:Results
PIONEER 11	A1+A2+A3	SEMA_PO	31	arm, events	0 / 390	arms_combined	R0019663:Table 3
PIONEER 11	A4	PLACEBO	31	arm, events	0 / 131		R0019663:Table 3
SUSTAIN™ 5	A1+A2	SEMA_SC	35	arm, events	0 / 264	arms_combined	R0012671:Table 2
SUSTAIN™ 5	A3	PLACEBO	35	arm, events	0 / 133		R0012671:Table 2
DUAL™ I Japan	A1	IDEGLIRA_SC	53	arm, events	0 / 275		registry:adverse_events
DUAL™ I Japan	A2	INS_DEGLUDEC	53	arm, events	0 / 271		registry:adverse_events
DUAL™ I Japan	A3	LIRA_SC	53	arm, events	0 / 273		registry:adverse_events
NCT05086445	A1	PLACEBO	14	arm, events	0 / 11		R0003844:Table 2
NCT05086445	A2+A3+A4	ORFO_PO	14	arm, events	0 / 49	arms_combined	R0003844:Table 2
LIXILAN JP-O1	A1	IGLARLIXI_SC	52.43	arm, events	0 / 161		R0015751:Table 3
LIXILAN JP-O1	A2	LIXI_SC	52.43	arm, events	0 / 160		R0015751:Results
NCT02887625	A1	EXENER_SC	78.21	arm, events	0 / 129		R0026120:Supplementary Table 1
NCT02887625	A2	OTHER_ACTIVE_basal_bolus_insulin	78.21	arm, events	0 / 122		R0026120:Supplementary Table 1
SUSTAIN™	A1+A2	SEMA_SC	35	arm, events	0 / 205	arms_combined	R0014736:Table 2
SUSTAIN™	A3	SITAGLIPTIN	35	arm, events	0 / 103		R0014736:Table 2
NCT02288273	A1	EXENER_SC	14	arm, events	0 / 61		R0025397:Results
NCT02288273	A2	PLACEBO	14	arm, events	0 / 56		R0025397:Results
Lixilan-L-CN	A1	IGLARLIXI_SC	30.43	arm, events	0 / 212		R0014540:Table 3
Lixilan-L-CN	A2	INS_GLARGINE	30.43	arm, events	0 / 214		R0014540:Table 3
GETGOAL-M	A1+A2	LIXI_SC	24	arm, events	0 / 510	arms_combined	R0025872:Table 2
GETGOAL-M	A3	PLACEBO	24	arm, events	0 / 170	printed_denominator	R0025872:Table 2
NCT01455441	A1	LIRA_SC	16	arm, events	0 / 18		R0010221:Results
NCT01455441	A2	PLACEBO	16	arm, events	0 / 16		R0010221:Results
NCT03311724	A1	PLACEBO	16	arm, events	0 / 26		R0010282:Table 2
NCT03311724	A2+A3+A4	TIRZ_SC	16	arm, events	0 / 85	arms_combined	R0010282:Table 2
NCT04466904	A2+A3	MAZD_SC	20	arm, events	0 / 16	arms_combined	R0009340:Table 2
NCT04466904	A4	DULA_SC	20	arm, events	0 / 6	printed_denominator	R0009340:Table 2
NCT04466904	A5	PLACEBO	20	arm, events	0 / 12	printed_denominator	R0009340:Table 2
NCT00700817	A1+A2	LIRA_SC	52	arm, events	0 / 446	arms_combined	R0024199:Table 2
NCT00700817	A3	SITAGLIPTIN	52	arm, events	0 / 219		R0024199:Table 2
S002858	A1	LIXI_SC	24	arm, events	0 / 51		R0001573:Supplement Table S2
S002858	A2	PLACEBO	24	arm, events	0 / 50		R0001573:Supplement Table S2
S002885	A1	DULA_SC	12	arm, events	0 / 13		R0003420:Results
S002885	A2	EMPAGLIFLOZIN	12	arm, events	0 / 12		R0003420:Results
S002928	A1	PLACEBO	24	arm, events	0 / 41		R0007034:Results
S002928	A2+A3	PEGLOX_SC	24	arm, events	0 / 82	arms_combined	R0007034:Results
S002984	A1	PEGLOX_SC	24	arm, events	0 / 39		R0011969:Supplement Table S2
S002984	A2	INS_GLARGINE	24	arm, events	0 / 39		R0011969:Supplement Table S2
S002992	A1	IGLARLIXI_SC	26.43	arm, events	0 / 443		R0010673:Results
S002992	A2	INS_PREMIX	26.43	arm, events	0 / 444		R0010673:Results
S003047	A1+A2	LIXI_SC	6.57	arm, events	0 / 80	printed_denominator;arms_combined	R0016337:Results
S003047	A3	PLACEBO	6.57	arm, events	0 / 40	printed_denominator	R0016337:Results
S003079	A1	EXEN_SC	5	arm, events	0 / 18		R0025923:Results
S003079	A2	STANDARD_CARE	5	arm, events	0 / 18		R0025923:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab